Navigation Links
In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
Date:7/15/2013

BURLINGTON, Mass., July 15, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European oncologists' prescribing decisions for second-line metastatic colorectal cancer. Clinical data and the opinions of interviewed thought leaders, however, indicate that current and emerging therapies have no advantage over the sales-leader bevacizumab (Genentech/Roche/Chugai's Avastin)/FOLFIRI (5-fluorouracil, leucovorin and irinotecan) on overall survival, one of the greatest unmet needs in second-line metastatic colorectal cancer. However, opinion leaders express optimism that clinical trial data could show that the mechanism of action of Eli Lilly/ImClone's ramucirumab could confer a benefit on progression-free survival.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled As the Second-Line Treatment Setting for Colorectal Cancer Becomes More Crowded, How Will Oncologists and Payers Differentiate Among New Therapies?  finds that surveyed U.S. oncologists would prescribe ramucirumab, in combination with FOLFIRI, to a median of 20 percent of their second-line drug-treated, metastatic colorectal cancer patients. This modest patient share demonstrates the struggle that a new agent will face penetrating the familiarity of Avastin, as well as strong competition from aflibercept (Sanofi/Regeneron's Zaltrap) and regorafenib (Bayer Healthcare's Stivarga), the latter of which is currently used primarily in later lines of treatment.

The findings also reveal that the safety and tolerability of second-line therapies for metastatic colorectal cancer are another important consideration in oncologists' prescribing decisions, as the incidence of colorectal cancer increases with age and, as a result, therapies in this setting have a great impact on the quality of life in an elderly population.  

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in median overall survival over currently available therapies, but while some emerging therapies hold promise, they are unlikely to match payers' requirements for widespread inclusion on their formularies.

"Avastin in combination with FOLFIRI is currently the most widely used regimen for the second-line treatment of metastatic colorectal cancer," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "An emerging therapy like ramucirumab will find it difficult to penetrate the already crowded second-line market, given physicians' familiarity with Avastin. However, if ramucirumab can show competitive advantages in efficacy, and safety in Phase III trials, we believe it has the potential to compete strongly following its anticipated launch in 2015."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelerate Diagnostics Announces Final Terms of Rights Offering
2. Cancer Vaccine Partnering Terms and Agreements
3. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
4. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
7. Sonendo Agrees To Terms For Up To $20 Million In Financing
8. Vaccine Partnering Terms and Agreements
9. Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
10. Side Effects Limit Prescription Drug Compliance
11. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ALBANY, New York , February 23, 2017 /PRNewswire/ ... Global Cardiac Holter Monitor Market are GE Healthcare, Koninklijke ... share of about 48% in the global market in ... are the two key factors assessed to be aiding ... Transparency Market Research states that the players in the ...
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... 2017   SeraCare Life Sciences , a ... diagnostics manufacturers and clinical laboratories, is announcing an ... NGS-Based Tests" to be hosted by GenomeWeb ... Eastern Standard Time (US). The goal ... for improved performance and global standardization in the ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... CO (PRWEB) , ... February 23, 2017 , ... The ... announce the winner of the 2016 National Education Policy Center Bunkum Award. We invite ... reviewed in 2016. , This year’s Bunkum winner is the Center for American Progress ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
Breaking Medicine News(10 mins):